Comparison of clinical, functional, and laboratory data depending on cough intensity
| Parameters | Group 1 (n = 29) | Group 2 (n = 72) | Group 3 (n = 21) | P-value |
|---|---|---|---|---|
| z FVC | 1.15 ± 1.25 | 1.14 ± 1.41 | 0.98 ± 1.08 | 0.876 |
| z FEV1 | 0.64 ± 0.98 | 0.35 ± 1.26 | –0.28 ± 1.28 | 0.028 |
| z FEV1/FVC | –0.67 ± 1.18 | –0.97 ± 1.31 | –1.65 ± 1.03 | 0.022 |
| Changes of FEV1 in tests with salbutamol, n = 50 | 1.06 ± 0.05 | 1.10 ± 0.09 | 1.19 ± 0.15 | 0.024 |
| PNIF, L/min | 45.53 ± 12.33 | 45.73 ± 13.10 | 39.67 ± 15.73 | 0.179 |
| PNIF/FVC | 10.52 [8.63; 14.85] | 11.65 [8.58; 14.97] | 9.72 [6.91; 11.95] | 0.089 |
| PNIF/FVC (without children with polyps in the cavity of the nasal passages), n = 114 | 10.95 [8.86; 15.72] | 12.11 [8.98; 15.11] | 9.27 [6.91; 11.95] | 0.035 |
| SNOT-22, score | 0.0 [0.0; 1.0] | 2.0 [0.0; 2.0] | 2.0 [1.0; 3.0] | < 0.001 |
| Postnasal discharge, score | 0.0 [0.0; 1.0] | 2.0 [0.0; 2.0] | 2.0 [2.0; 3.0] | < 0.001 |
| Eosinophils, 109/L | 0.19 [0.10; 0.32] | 0.29 [0.15; 0.60] | 0.35 [0.16; 0.50] | 0.132 |
| Total IgE, ME/mL | 182.69 [86.83; 298.43] | 173.50 [81.55; 356.70] | 187.58 [62.20; 724.69] | 0.685 |
Group 1: no cough (0 points on SNOT-22); Group 2: mild cough (1–2 points according to SNOT-22); Group 3: cough of moderate intensity (3–4 points according to SNOT-22). PNIF: peak nasal inspiratory flow; FVC: forced vital capacity of the lungs; FEV1: forced expiratory volume in the first second; SNOT-22: Sinonasal Outcome Test-22; IgE: immunoglobulin E. The data is presented in the form of Me [Q1; Q3], where Me is the median, [Q1; Q3] is 1st and 3rd quartiles in the case of an abnormal distribution of quantities, and in the form of M ± σ, where M is the mean value, σ is the standard deviation in the case of their normal distribution
